Evidence map›Paper›PMID 36293183›Full record

ArticleInternational journal of molecular sciences2022

Candesartan Does Not Activate PPARγ and Its Target Genes in Early Gestation Trophoblasts.

Lena Neuper, Daniel Kummer, Désirée Forstner, Jacqueline Guettler, Nassim Ghaffari-Tabrizi-Wizsy, Cornelius Fischer, Herbert Juch, Olivia Nonn, Martin Gauster

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Molecular Research on Reproductive Toxicity.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Lena NeuperDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.
Daniel KummerDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.
Désirée ForstnerDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0001-5451-7580
Jacqueline GuettlerDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0002-8141-5712
Nassim Ghaffari-Tabrizi-WizsyDivision of Immunology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, 8010 Graz, Austria.
Cornelius FischerInstitute for Medical Systems Biology (BIMSB), 10115 Berlin, Germany.
Herbert JuchDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.
Olivia NonnDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0001-6385-2866
Martin GausterDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0003-0386-6857
Medical University of Graz · AT

Funding

Austrian Science Fund FWF DOC 31
6 · The paper itself

Abstract

Angiotensin II receptor 1 blockers are commonly used to treat hypertension in women of childbearing age. While the fetotoxic effects of these drugs in the second and third trimesters of pregnancy are well documented, their possible impacts on placenta development in early gestation are unknown. Candesartan, a member of this group, also acts as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, a key regulator shown to be important for placental development. We have previously shown that trophoblasts do not express the candesartan target-receptor angiotensin II type 1 receptor AGTR1. This study investigated the possible role of candesartan on trophoblastic PPARγ and its hallmark target genes in early gestation. Candesartan did not affect the PPARγ protein expression or nuclear translocation of PPARγ. To mimic extravillous trophoblasts (EVTs) and cytotrophoblast/syncytiotrophoblast (CTB/SCT) responses to candesartan, we used trophoblast cell models BeWo (for CTB/SCT) and SGHPL-4 (EVT) cells as well as placental explants. In vitro, the RT-qPCR analysis showed no effect of candesartan treatment on PPARγ target genes in BeWo or SGHPL-4 cells. Treatment with positive control rosiglitazone, another PPARγ agonist, led to decreased expressions of

Indexed as

PPAR gammaTrophoblastsAngiotensin IIBenzimidazolesBiphenyl CompoundsFemaleHumansPlacentaPlacentationPregnancyReceptor, Angiotensin, Type 1RosiglitazoneTetrazolesAngiotensin IIBenzimidazolesBiphenyl CompoundscandesartanPPAR gammaReceptor, Angiotensin, Type 1RosiglitazoneTetrazolesangiotensin IIcandesartanfirst-trimester pregnancyplacentaPPARγrosiglitazoneteratogenictrophoblast

Identifiers

PMID36293183
PMCPMC9603971
OpenAlexW4306385432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.